ライフサイエンスコーパス: dyslipidaemia

1 was reduced in a sample from a patient with dyslipidaemia.

2 ection and atherosclerosis in the context of dyslipidaemia.

3 ds and apolipoproteins in patients with mild dyslipidaemia.

4 ETP) inhibitor TA-8995 in patients with mild dyslipidaemia.

5 vious phase 1 and 2 studies of patients with dyslipidaemia.

6 ce of physical activity for individuals with dyslipidaemia.

7 e/nonalcoholic fatty liver disease/metabolic dyslipidaemia.

8 nalcoholic fatty liver disease and metabolic dyslipidaemia.

9 sive genes and causes insulin resistance and dyslipidaemia.

10 d a potential new mechanism for treatment of dyslipidaemia.

11 9] mg/dL) decrease in LDL-C in patients with dyslipidaemia.

12 in versus pravastatin in adults with HIV and dyslipidaemia.

13 diac deaths occur in people with atherogenic dyslipidaemias.

14 1.25-2.56), diabetes (2.31, 1.61-3.31), and dyslipidaemia (2.07, 1.01-4.26) were independent predict

15 central obesity, diabetes, hypertension, and dyslipidaemia, 26.7% (26.2-27.2) had one, 30.2% (29.7-30

16 essure (27/57 [47%] vs 9/55 [16%]; p=0.001), dyslipidaemia (48/56 [86%] vs 21/55 [38%]; p<0.0001), an

17 rtension associates with insulin resistance, dyslipidaemia and abdominal obesity, the identification

18 n syndromes associated with type 2 diabetes, dyslipidaemia and associated cardiac, renal and hepatic

19 Dyslipidaemia and autoimmune diseases were significantly

20 lic parameters including insulin resistance, dyslipidaemia and body mass index are increasingly recog

21 ns are commonly prescribed for management of dyslipidaemia and cardiovascular disease.

22 , hyperuricosuria, spontaneous hypertension, dyslipidaemia and elevated body fat.

23 by reducing fat mass and markedly improving dyslipidaemia and hyperglycaemia.

24 ate are reasonable second-line therapies for dyslipidaemia and in diabetes, and well tolerated in com

25 ate are reasonable second-line therapies for dyslipidaemia and in diabetes.

26 xcess adiposity, impaired glycaemic control, dyslipidaemia and moderate hypertension.

27 seases share many common features, including dyslipidaemia and transaminitis.

28 nifestations of disordered lipid metabolism (dyslipidaemia) and its management.

29 6.7) for hypertension, 34.5% (34.0-35.0) for dyslipidaemia, and 18.6% (18.2-19.0) for metabolic syndr

30 The metabolic dysfunction, dyslipidaemia, and inflammation caused by obesity contri

31 e hyperinsulinaemia, insulin resistance, and dyslipidaemia, and the syndrome is associated with great

32 nalcoholic fatty liver disease and metabolic dyslipidaemia are inextricably linked and need to be con

33 PURPOSE OF REVIEW: Dyslipidaemias are noted in all stages of chronic kidney

34 Metabolic syndrome, abdominal obesity and dyslipidaemia, are strongly associated with polyneuropat

35 ging cholesterol metabolism and diet induced dyslipidaemia, as well as insulin sensitivity in metabol

36 that the pathogenic molecular mechanisms of dyslipidaemias contribute directly to arrhythmogenesis.

37 Univariate analysis identified a history of dyslipidaemia, coronary artery disease, diastolic blood

38 and two or more comorbidities (hypertension, dyslipidaemia, diabetes or prediabetes, or abdominal obe

39 ess include central obesity, hyperglycaemia, dyslipidaemia, electrolyte abnormalities and hypertensio

40 tures induced by high-fat diet (HF), such as dyslipidaemia, glucose intolerance and hypertension.

41 syndrome' - obesity, insulin resistance and dyslipidaemia -- has conspired to produce a worldwide ep

42 nts with a significant degree of atherogenic dyslipidaemia (high triglycerides and low HDL-cholestero

43 murine model of FH transiently corrected the dyslipidaemia; however, humoral and cellular immune resp

44 peutic effect on obesity, hyperglycaemia and dyslipidaemia; however, its effect on NAFLD has yet to b

45 ) are established agents in the treatment of dyslipidaemia, hyperglycaemia, and insulin resistance.

46 iated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesi

47 , insulin resistance, glucose metabolism and dyslipidaemia in Alstrom syndrome will be discussed as w

48 atin as a preferred drug in the treatment of dyslipidaemia in people with HIV.

49 c disease component (hypertension, diabetes, dyslipidaemia) in the index year were considered "metabo

50 mellitus is the consequence of the diabetic dyslipidaemia, in particular post-prandial lipaemia, and

51 cluding smoking, hypertension, diabetes, and dyslipidaemia-increased.

52 Diabetic dyslipidaemia is an important risk factor and is open to

53 Dyslipidaemia is an important risk factor for cardiovasc

54 Management of dyslipidaemia is crucial for the reduction in the risk o

55 retroviral therapy for at least 6 months and dyslipidaemia (LDL cholesterol 3.4-5.7 mmol/L and trigly

56 In the first study, 50 patients with dyslipidaemia (LDL-C 100-190 mg/dL; 40 active, 10 placeb

57 Age, family history, Fasting Blood Glucose, dyslipidaemia, lipid profile, parity and use of oral con

58 Individuals with mixed dyslipidaemia may require combination therapy to achieve

59 , hypertension, smoking, poor diet, obesity, dyslipidaemia, metabolic syndrome, low physical activity

60 esity, impairment of glucose metabolism, and dyslipidaemia; musculoskeletal disorders, such as myopat

61 ncreased blood pressure, insulin resistance, dyslipidaemia, obesity and mesenteric artery endothelial

62 omplicated obesity or BMI 27-45 kg/m(2) with dyslipidaemia or hypertension were eligible for enrolmen

63 erolaemia or any condition causing secondary dyslipidaemia, or a history of statin intolerance, diabe

64 alcoholic steatohepatitis (NASH), hereditary dyslipidaemia, or cryptogenic cirrhosis.

65 e--ie, the roles of hyperglycaemia, diabetic dyslipidaemia (other than the control of LDL-cholesterol

66 the risk of hypertension, hyperglycaemia and dyslipidaemia, recognized as the metabolic syndrome.

67 Dyslipidaemia remains a significant risk factor for card

68 Localized dyslipidaemia, secondary to cholestasis, was investigate

69 re drugs available to test the hypothesis of dyslipidaemias-specific prevention of electrophysiologic

70 In the dyslipidaemia study, one patient withdrew consent and on

71 LDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk

72 reciated that inflammatory mechanisms couple dyslipidaemia to atheroma formation.

73 for the treatment or prevention of adult HIV dyslipidaemia, versus no or other intervention were incl

74 Dyslipidaemia was found in 69.4% of patients, 60% of FDR

75 rtension, diabetes, myocardial infarction or dyslipidaemia were not.

76 Drugs for hyperglycaemia, hypertension, and dyslipidaemia were prescribed by protocol.

77 recently only diabetic patients with marked dyslipidaemia were routinely offered lipid-lowering ther

78 Treatment of dyslipidaemia with statins has been challenging in peopl